Drug Trial Radar · NCT03257267
Study of Cemiplimab in Adults With Cervical Cancer
Last checked: Nov 20, 2026Latest source record: Apr 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
608
Actual
Start
Sep 5, 2017
Primary completion
Mar 15, 2021
Study completion Apr 20, 2023
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- Collaborators
- Sanofi
- First posted
- Aug 22, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective is to compare overall survival (OS) for patients with recurrent or metastatic cervical cancer who have histology of squamous cell carcinoma (SCC) and who have any eligible histology treated with either cemiplimab or investigator's choice (IC) chemotherapy. The secondary objectives performed among SCC patients and among all eligible histologies (SCC and adenocarcinoma/adenosquamous carcinoma (AC) are: * To compare progression-free survival (PFS) of cemiplimab versus IC chemotherapy * To compare objective response rate (ORR) (partial response \[PR\] + complete response \[CR\]) of cemiplimab versus IC chemotherapy per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 * To compare the duration of response (DOR) of cemiplimab versus IC chemotherapy * To compare the safety profiles of cemiplimab versus IC chemotherapy by describing adverse events (AE) * To compare quality of life (QOL) for patients treated with cemiplimab versus IC chemotherapy using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Conditions
- Squamous Cell Carcinoma (SCC)
- Recurrent or Metastatic, Platinum-refractory Cervical Cancer
Interventions
CemiplimabDrug
Intravenous (IV) administration every 3 weeks (Q3W)
Investigator Choice (IC) ChemotherapyDrug
IC chemotherapy options include: 1. Antifolate: Pemetrexed 2. Topoisomerase 1 inhibitor: Topotecan or Irinotecan 3. Nucleoside analogue: Gemcitabine 4. Vinca alkaloid: Vinorelbine The only chemotherapy treatments allowed in the control arm are any of the 5 drugs that are listed as IC options above.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS)Time frame: From first dose up to 90 following last dose (~42 months)
- Overall Survival (OS) in the SCC PopulationTime frame: From first dose up to 90 following last dose (~42 months)
Locations
105 sites in 14 countries. Site status is shown where the registry gives one.
Arizona Oncology Associates
Phoenix, Arizona
Arizona Oncology Associates
Tucson, Arizona
University of California Irvine
Orange, California
Ochsner Clinic Foundation
New Orleans, Louisiana
Cancer Research for the Ozarks
Springfield, Missouri
New York Presbyterian Queens
Flushing, New York
Northwell Health
Lake Success, New York
Laura and Issac Perlmutter Cancer Center at NYU Langone
New York, New York
First Health of the Carolinas Outpatient Cancer Center
Pinehurst, North Carolina
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania
Texas Oncology, P.A.
Austin, Texas
St. George Hospital
Kogarah, New South Wales, Australia
Northern NSW Health District, The Tweed Hospital
Tweed Heads, New South Wales, Australia
Royal Brisbane & Women's Hospital
Herston, Queensland, Australia
Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia
Sir Charles Gairdner Hospital
Nedlands, Western Australia, Australia
St. John of God Subiaco Hospital
Subiaco, Western Australia, Australia
OLV ziekenhuis Aalst, Medische oncologie- Radiotherapie
Aalst, Belgium
Institut Bordet
Brussels, Belgium
Cliniques universitaires Saint-Luc
Brussels, Belgium
UZLeuven Gynaelologic Oncology
Leuven, Belgium
CHC Saint Joseph
Liège, Belgium
CHU Liège
Liège, Belgium
CHU UCL Namur site Sainte Elisabeth
Namur, Belgium
Instituto de Pesquisas Clinicas para Estudos Multicentricos - IPCEM
Caxias do Sul, Brazil
Instituto Nacional de Cancer - INCA
Rio de Janeiro, Brazil
Instituto COI de Pesquisa
Rio de Janeiro, Brazil
Liga Norte Riograndense Contra o Câncer
Natal, Rio Grande do Norte, Brazil
Hosptial Sao Lucas da PUC de Porto Alegre
Porto Alegre, Rio Grande do Sul, Brazil
Irmandade da Santa Casa de Misericórdia de Porto Alegre
Porto Alegre, Rio Grande do Sul, Brazil
Centro de Novos Tratamentos Itajai
Itajaí, Santa Catarina, Brazil
Fundação Pio XII - Hospital de Câncer de Barretos
Barretos, São Paulo, Brazil
Tom Baker Cancer Center
Calgary, Alberta, Canada
British Columbia Cancer Agency
Vancouver, British Columbia, Canada
London Health Sciences Centre
London, Ontario, Canada
Princess Margaret Cancer Centre
Toronto, Ontario, Canada
Hospital Maisonneuve-Rosemont
Montreal, Quebec, Canada
Hopital Notre-Dame du Centre Hospitalier de l'Universite de Montreal
Montreal, Quebec, Canada
Jewish General Hospital
Montreal, Quebec, Canada
General Hospital of Athens Alexandra
Athens, Greece
Showing 40 of 105 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.